{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T13:38:59Z","timestamp":1782740339965,"version":"3.54.5"},"reference-count":114,"publisher":"Elsevier","isbn-type":[{"value":"9780128246160","type":"print"}],"license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021]]},"DOI":"10.1016\/bs.acc.2020.10.001","type":"book-chapter","created":{"date-parts":[[2020,12,24]],"date-time":"2020-12-24T16:34:20Z","timestamp":1608827660000},"page":"191-214","source":"Crossref","is-referenced-by-count":20,"title":["Synthetic drugs of abuse"],"prefix":"10.1016","member":"78","reference":[{"key":"10.1016\/bs.acc.2020.10.001_bb0010","series-title":"2019 National Drug Threat Assessment","author":"Drug Enforcement Administration","year":"2020"},{"key":"10.1016\/bs.acc.2020.10.001_bb0015","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/cpt.575","article-title":"Designer drugs 2.0","volume":"101","author":"Huestis","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/bs.acc.2020.10.001_bb0020","series-title":"2016 National Drug Threat Assessment Summary","author":"Drug Enforcement Administration","year":"2016"},{"key":"10.1016\/bs.acc.2020.10.001_bb0025","series-title":"2017 National Drug Threat Assessment","author":"Drug Enforcement Administration","year":"2017"},{"key":"10.1016\/bs.acc.2020.10.001_bb0030","doi-asserted-by":"crossref","first-page":"e20171330","DOI":"10.1542\/peds.2017-1330","article-title":"Synthetic cannabinoid use among high school seniors","volume":"140","author":"Palamar","year":"2017","journal-title":"Pediatrics"},{"key":"10.1016\/bs.acc.2020.10.001_bb0035","author":"European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)"},{"key":"10.1016\/bs.acc.2020.10.001_bb0040","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/164_2019_260","article-title":"Newly emerging drugs of abuse","volume":"258","author":"Tamama","year":"2020","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/bs.acc.2020.10.001_bb0045","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.drugalcdep.2014.08.005","article-title":"Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications","volume":"144","author":"Castaneto","year":"2014","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/bs.acc.2020.10.001_bb0050","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.bmc.2004.09.050","article-title":"Structure-activity relationships for 1-alkyl-3-(1-naphthoyl)indoles at the cannabinoid CB(1) and CB(2) receptors: steric and electronic effects of naphthoyl substituents. New highly selective CB(2) receptor agonists","volume":"13","author":"Huffman","year":"2005","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/bs.acc.2020.10.001_bb0055","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s12229-015-9157-3","article-title":"Evolution and classification of Cannabis sativa (Marijuana, Hemp) in relation to human utilization","volume":"81","author":"Small","year":"2015","journal-title":"Bot Rev."},{"key":"10.1016\/bs.acc.2020.10.001_bb0060","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.jep.2018.09.004","article-title":"Cannabis sativa: a comprehensive ethnopharmacological review of a medicinal plant with a long history","volume":"227","author":"Bonini","year":"2018","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/bs.acc.2020.10.001_bb0065","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0021917","article-title":"Phase I hydroxylated metabolites of the K2 synthetic cannabinoid JWH-018 retain in vitro and in vivo cannabinoid 1 receptor affinity and activity","volume":"6","author":"Brents","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/bs.acc.2020.10.001_bb0070","doi-asserted-by":"crossref","first-page":"256","DOI":"10.4103\/1947-2714.185038","article-title":"Acute rhabdomyolysis following synthetic cannabinoid ingestion","volume":"8","author":"Adedinsewo","year":"2016","journal-title":"N. Am. J. Med. Sci."},{"key":"10.1016\/bs.acc.2020.10.001_bb0075","doi-asserted-by":"crossref","first-page":"760","DOI":"10.3109\/15563650.2011.609822","article-title":"Severe toxicity following synthetic cannabinoid ingestion","volume":"49","author":"Lapoint","year":"2011","journal-title":"Clin. Toxicol. (Phila.)"},{"key":"10.1016\/bs.acc.2020.10.001_bb0080","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/phar.2241","article-title":"Synthetic cannabinoid-associated multiple organ failure: case series and literature review","volume":"39","author":"Armstrong","year":"2019","journal-title":"Pharmacotherapy"},{"key":"10.1016\/bs.acc.2020.10.001_bb0085","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1177\/0269881115574493","article-title":"Risk of emergency medical treatment following consumption of cannabis or synthetic cannabinoids in a large global sample","volume":"29","author":"Winstock","year":"2015","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/bs.acc.2020.10.001_bb0090","doi-asserted-by":"crossref","first-page":"e1622","DOI":"10.1542\/peds.2010-3823","article-title":"Myocardial infarction associated with use of the synthetic cannabinoid K2","volume":"128","author":"Mir","year":"2011","journal-title":"Pediatrics"},{"key":"10.1016\/bs.acc.2020.10.001_bb0095","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.forsciint.2019.02.021","article-title":"Death cases involving certain new psychoactive substances: a review of the literature","volume":"298","author":"Kraemer","year":"2019","journal-title":"Forensic Sci. Int."},{"key":"10.1016\/bs.acc.2020.10.001_bb0100","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1056\/NEJMp1505328","article-title":"Synthetic cannabinoid-related illnesses and deaths","volume":"373","author":"Trecki","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.acc.2020.10.001_bb0105","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1002\/jms.1558","article-title":"'Spice' and other herbal blends: harmless incense or cannabinoid designer drugs?","volume":"44","author":"Auwarter","year":"2009","journal-title":"J. Mass Spectrom."},{"key":"10.1016\/bs.acc.2020.10.001_bb0110","series-title":"Understanding the \u2018Spice\u2019 Phenomenon","author":"European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)","year":"2009"},{"key":"10.1016\/bs.acc.2020.10.001_bb0115","doi-asserted-by":"crossref","first-page":"910","DOI":"10.3109\/15563650.2011.635149","article-title":"2010 annual report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 28th annual report","volume":"49","author":"Bronstein","year":"2011","journal-title":"Clin. Toxicol. (Phila.)"},{"key":"10.1016\/bs.acc.2020.10.001_bb0120","doi-asserted-by":"crossref","first-page":"162","DOI":"10.3389\/fpubh.2018.00162","article-title":"Synthetic and non-synthetic cannabinoid drugs and their adverse effects\u2014a review from public health prospective","volume":"6","author":"Cohen","year":"2018","journal-title":"Front. Public Health"},{"key":"10.1016\/bs.acc.2020.10.001_bb0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/15563650.2015.1110590","article-title":"A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment","volume":"54","author":"Tait","year":"2016","journal-title":"Clin. Toxicol. (Phila.)"},{"key":"10.1016\/bs.acc.2020.10.001_bb0130","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1080\/08897077.2016.1219438","article-title":"Acute effects of synthetic cannabinoids: update 2015","volume":"38","author":"Tournebize","year":"2017","journal-title":"Subst. Abus."},{"key":"10.1016\/bs.acc.2020.10.001_bb0135","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/dar.12225","article-title":"Synthetic cannabinoid withdrawal: a new demand on detoxification services","volume":"34","author":"Macfarlane","year":"2015","journal-title":"Drug Alcohol Rev."},{"key":"10.1016\/bs.acc.2020.10.001_bb0140","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1097\/ADM.0b013e31828e1881","article-title":"The synthetic cannabinoid withdrawal syndrome","volume":"7","author":"Nacca","year":"2013","journal-title":"J. Addict. Med."},{"key":"10.1016\/bs.acc.2020.10.001_bb0145","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1021\/jm00165a024","article-title":"Cannabimimetic activity of novel enantiomeric, benzofuran cannabinoids","volume":"33","author":"Mechoulam","year":"1990","journal-title":"J. Med. Chem."},{"key":"10.1016\/bs.acc.2020.10.001_bb0150","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S0022-3565(25)33364-1","article-title":"Cannabimimetic activity from CP-47,497, a derivative of 3-phenylcyclohexanol","volume":"223","author":"Weissman","year":"1982","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/bs.acc.2020.10.001_bb0155","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.2174\/0929867054020864","article-title":"Recent developments in the medicinal chemistry of cannabimimetic indoles, pyrroles and indenes","volume":"12","author":"Huffman","year":"2005","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/bs.acc.2020.10.001_bb0160","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.lfs.2013.09.011","article-title":"Moving around the molecule: relationship between chemical structure and in vivo activity of synthetic cannabinoids","volume":"97","author":"Wiley","year":"2014","journal-title":"Life Sci."},{"key":"10.1016\/bs.acc.2020.10.001_bb0165","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.drudis.2009.04.003","article-title":"Navigating structure-activity landscapes","volume":"14","author":"Bajorath","year":"2009","journal-title":"Drug Discov. Today"},{"key":"10.1016\/bs.acc.2020.10.001_bb0170","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.neuro.2018.11.004","article-title":"Cannabinoid-like effects of five novel carboxamide synthetic cannabinoids","volume":"70","author":"Gatch","year":"2018","journal-title":"Neurotoxicology"},{"key":"10.1016\/bs.acc.2020.10.001_bb0175","series-title":"2018 National Drug Threat Assessment","author":"Drug Enforcement Administration","year":"2018"},{"key":"10.1016\/bs.acc.2020.10.001_bb0180","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1080\/15563650.2019.1690149","article-title":"An outbreak of severe coagulopathy from synthetic cannabinoids tainted with Long-Acting anticoagulant rodenticides","volume":"58","author":"Devgun","year":"2020","journal-title":"Clin. Toxicol. (Phila.)"},{"key":"10.1016\/bs.acc.2020.10.001_bb0185","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1056\/NEJMoa1807652","article-title":"An outbreak of synthetic cannabinoid-associated coagulopathy in Illinois","volume":"379","author":"Kelkar","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.acc.2020.10.001_bb0190","series-title":"2015 National Drug Threat Assessment","author":"Drug Enforcement Administration","year":"2015"},{"key":"10.1016\/bs.acc.2020.10.001_bb0195","author":"National Institute on Drug Abuse (NIDA)"},{"key":"10.1016\/bs.acc.2020.10.001_bb0200","series-title":"European Drug Report 2018: Trends and Developments","author":"European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)","year":"2018"},{"key":"10.1016\/bs.acc.2020.10.001_bb0205","series-title":"European Drug Report 2019: Trends and Developments","author":"European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)","year":"2019"},{"key":"10.1016\/bs.acc.2020.10.001_bb0210","article-title":"The use of synthetic cannabinoid receptor agonists (SCRAs) within the homeless population: motivations, harms and the implications for developing an appropriate response","author":"Gray","year":"2020","journal-title":"Addict Res Theory."},{"key":"10.1016\/bs.acc.2020.10.001_bb0215","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1747-597X-6-16","article-title":"College students and use of K2: an emerging drug of abuse in young persons","volume":"6","author":"Hu","year":"2011","journal-title":"Subst. Abuse Treat. Prev. Policy"},{"key":"10.1016\/bs.acc.2020.10.001_bb0220","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.3109\/15563650.2014.987397","article-title":"2013 annual report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 31st annual report","volume":"52","author":"Mowry","year":"2014","journal-title":"Clin. Toxicol. (Phila.)"},{"key":"10.1016\/bs.acc.2020.10.001_bb0225","series-title":"Monitoring the Future National Survey Results on Drug Use 1975\u20132019: Overview, Key Findings on Adolescent Drug Use","author":"Miech","year":"2020"},{"key":"10.1016\/bs.acc.2020.10.001_bb0230","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa1610300","article-title":"\"Zombie\" outbreak caused by the synthetic cannabinoid AMB-FUBINACA in New York","volume":"376","author":"Adams","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.acc.2020.10.001_bb0235","series-title":"New Psychoactive Substances in Europe. An Update From the EU Early Warning System","first-page":"2015","author":"European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)","year":"2015"},{"key":"10.1016\/bs.acc.2020.10.001_bb0240","doi-asserted-by":"crossref","first-page":"11476","DOI":"10.1021\/acs.analchem.6b02600","article-title":"Detection and activity profiling of synthetic cannabinoids and their metabolites with a newly developed bioassay","volume":"88","author":"Cannaert","year":"2016","journal-title":"Anal. Chem."},{"key":"10.1016\/bs.acc.2020.10.001_bb0245","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.bcp.2012.01.004","article-title":"Monohydroxylated metabolites of the K2 synthetic cannabinoid JWH-073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to partial agonist activity","volume":"83","author":"Brents","year":"2012","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/bs.acc.2020.10.001_bb0250","series-title":"Establishment of Drug Codes for 26 Substances","first-page":"664","volume":"vol. 78","author":"Drug Enforcement Administration","year":"2013"},{"key":"10.1016\/bs.acc.2020.10.001_bb0255","series-title":"Drugs of Abuse, A DEA Resource Guide","author":"Drug Enforcement Administration","year":"2020"},{"key":"10.1016\/bs.acc.2020.10.001_bb0260","series-title":"Schedules of Controlled Substances: Temporary Placement of 5F-EDMB-PINACA, 5F-MDMB-PICA, FUB-AKB48, 5F-CUMYL-PINACA, and FUB-144 into Schedule I 84, 15505\u201315511","author":"Drug Enforcement Administration","year":"2019"},{"key":"10.1016\/bs.acc.2020.10.001_bb0265","series-title":"New Psychoactive Substances in Europe: Legislation and Prosecution\u2014Current Challenges and Solutions, EMCDDA\u2013Eurojust Joint Publication","author":"European Monitoring Centre for Drugs and Drug Addiction and Eurojust","year":"2016"},{"key":"10.1016\/bs.acc.2020.10.001_bb0270","first-page":"79","article-title":"European dimension of cannabinoid-like products use","volume":"5","author":"Surugiu","year":"2012","journal-title":"J. Med. Life"},{"key":"10.1016\/bs.acc.2020.10.001_bb0275","series-title":"List of Psychotropic Substances Under International Control","doi-asserted-by":"crossref","DOI":"10.18356\/ebc7f183-en-fr-es","author":"International Narcotics Control Board (INCB)","year":"2019"},{"key":"10.1016\/bs.acc.2020.10.001_bb0280","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.jep.2010.07.001","article-title":"Khat chewing, cardiovascular diseases and other internal medical problems: the current situation and directions for future research","volume":"132","author":"Al-Motarreb","year":"2010","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/bs.acc.2020.10.001_bb0285","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s13181-011-0193-z","article-title":"The toxicology of bath salts: a review of synthetic cathinones","volume":"8","author":"Prosser","year":"2012","journal-title":"J. Med. Toxicol."},{"key":"10.1016\/bs.acc.2020.10.001_bb0290","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1021\/ja01395a032","article-title":"Synthesis homologs of d,l-ephedrine","volume":"50","author":"Hyde","year":"1928","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/bs.acc.2020.10.001_bb0295","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1016\/S0196-0644(05)80419-6","article-title":"Methcathinone: a Russian designer amphetamine infiltrates the rural midwest","volume":"22","author":"Emerson","year":"1993","journal-title":"Ann. Emerg. Med."},{"key":"10.1016\/bs.acc.2020.10.001_bb0300","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1177\/009286150103500134","article-title":"Evaluation of the characteristics of safety withdrawal of prescription drugs from worldwide pharmaceutical markets\u20141960 to 1999","volume":"35","author":"Fung","year":"2001","journal-title":"Drug Inf. J."},{"key":"10.1016\/bs.acc.2020.10.001_bb0305","first-page":"631","article-title":"Evaluation of pyrovalerone in chronically fatigued volunteers","volume":"13","author":"Gardos","year":"1971","journal-title":"Curr. Ther. Res. Clin. Exp."},{"key":"10.1016\/bs.acc.2020.10.001_bb0310","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1159\/000467975","article-title":"A controlled evaluation of pyrovalerone in chronically fatigued volunteers","volume":"8","author":"Goldberg","year":"1973","journal-title":"Int. Pharmacopsychiatry"},{"key":"10.1016\/bs.acc.2020.10.001_bb0315","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1056\/NEJMc1107097","article-title":"\"Bath salts\" intoxication","volume":"365","author":"Ross","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.acc.2020.10.001_bb0320","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drugalcdep.2013.06.016","article-title":"Clinical and pharmacological aspects of bath salt use: a review of the literature and case reports","volume":"132","author":"Miotto","year":"2013","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/bs.acc.2020.10.001_bb0325","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1080\/20009666.2018.1510711","article-title":"Fatal intoxication with N-ethylpentylone: a case report","volume":"8","author":"Ikeji","year":"2018","journal-title":"J. Commun. Hosp. Intern. Med. Perspect."},{"key":"10.1016\/bs.acc.2020.10.001_bb0330","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jflm.2019.04.012","article-title":"Fatal intoxication of a regular drug user following N-ethyl-hexedrone and ADB-FUBINACA consumption","volume":"65","author":"Kovacs","year":"2019","journal-title":"J. Forensic Leg. Med."},{"key":"10.1016\/bs.acc.2020.10.001_bb0335","first-page":"268","article-title":"Synthetic cathinones related fatalities: an update","volume":"22","author":"Zaami","year":"2018","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/bs.acc.2020.10.001_bb0340","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s11419-017-0385-6","article-title":"The newest cathinone derivatives as designer drugs: an analytical and toxicological review","volume":"36","author":"Majchrzak","year":"2018","journal-title":"Forensic Toxicol."},{"key":"10.1016\/bs.acc.2020.10.001_bb0345","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00204-013-1163-9","article-title":"Khat and synthetic cathinones: a review","volume":"88","author":"Valente","year":"2014","journal-title":"Arch. Toxicol."},{"key":"10.1016\/bs.acc.2020.10.001_bb0350","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1248\/yakushi1947.74.5_551","article-title":"Studies on alkanolamines. II. Synthesis of N-methyl-3,4-dihydroxyephedrine hydrochloride and its derivatives. Application of the Viogt reaction","volume":"74","author":"Iwao","year":"1954","journal-title":"Yakugaku Zasshi"},{"key":"10.1016\/bs.acc.2020.10.001_bb0355","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1248\/yakushi1947.74.5_548","article-title":"Studies on alkanolamines. I. Synthesis of N-methyl-3,4-dihydroxyephedrine hydrochloride and its derivatives","volume":"74","author":"Iwao","year":"1954","journal-title":"Yakugaku Zasshi"},{"key":"10.1016\/bs.acc.2020.10.001_bb0360","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1093\/jat\/bky022","article-title":"Dibutylone (bk-DMBDB): intoxications, quantitative confirmations and metabolism in authentic biological specimens","volume":"42","author":"Krotulski","year":"2018","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/bs.acc.2020.10.001_bb0365","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.forsciint.2013.04.015","article-title":"Designer cathinones\u2014an emerging class of novel recreational drugs","volume":"231","author":"Zawilska","year":"2013","journal-title":"Forensic Sci. Int."},{"key":"10.1016\/bs.acc.2020.10.001_bb0370","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/j.1476-5381.2012.02145.x","article-title":"Pharmacological characterization of designer cathinones in vitro","volume":"168","author":"Simmler","year":"2013","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/bs.acc.2020.10.001_bb0375","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1248\/yakushi.128.1499","article-title":"Analysis of designer drugs detected in the products purchased in fiscal year 2006","volume":"128","author":"Uchiyama","year":"2008","journal-title":"Yakugaku Zasshi"},{"key":"10.1016\/bs.acc.2020.10.001_bb0380","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.drugalcdep.2015.08.028","article-title":"Self-reported use of novel psychoactive substances in a US nationally representative survey: prevalence, correlates, and a call for new survey methods to prevent underreporting","volume":"156","author":"Palamar","year":"2015","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/bs.acc.2020.10.001_bb0385","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s00213-018-4985-6","article-title":"A review of the influence of functional group modifications to the core scaffold of synthetic cathinones on drug pharmacokinetics","volume":"236","author":"Calinski","year":"2019","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/bs.acc.2020.10.001_bb0390","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/jat\/bku021","article-title":"Testing for designer stimulants: metabolic profiles of 16 synthetic cathinones excreted free in human urine","volume":"38","author":"Uralets","year":"2014","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/bs.acc.2020.10.001_bb0395","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1007\/s00216-010-3636-5","article-title":"Beta-keto amphetamines: studies on the metabolism of the designer drug mephedrone and toxicological detection of mephedrone, butylone, and methylone in urine using gas chromatography-mass spectrometry","volume":"397","author":"Meyer","year":"2010","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/bs.acc.2020.10.001_bb0400","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.forsciint.2017.01.021","article-title":"Toxicological investigation of forensic cases related to the designer drug 3,4-methylenedioxypyrovalerone (MDPV): detection, quantification and studies on human metabolism by GC-MS","volume":"273","author":"Grapp","year":"2017","journal-title":"Forensic Sci. Int."},{"key":"10.1016\/bs.acc.2020.10.001_bb0405","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1080\/00498250600780191","article-title":"Metabolism of the recently encountered designer drug, methylone, in humans and rats","volume":"36","author":"Kamata","year":"2006","journal-title":"Xenobiotica"},{"key":"10.1016\/bs.acc.2020.10.001_bb0410","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.forsciint.2009.04.001","article-title":"Determination of the metabolites of the new designer drugs bk-MBDB and bk-MDEA in human urine","volume":"188","author":"Zaitsu","year":"2009","journal-title":"Forensic Sci. Int."},{"key":"10.1016\/bs.acc.2020.10.001_bb0415","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1002\/jms.1859","article-title":"Studies on the metabolism of the alpha-pyrrolidinophenone designer drug methylenedioxy-pyrovalerone (MDPV) in rat and human urine and human liver microsomes using GC-MS and LC-high-resolution MS and its detectability in urine by GC-MS","volume":"45","author":"Meyer","year":"2010","journal-title":"J. Mass Spectrom."},{"key":"10.1016\/bs.acc.2020.10.001_bb0420","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1002\/jms.1571","article-title":"New designer drug alpha-pyrrolidinovalerophenone (PVP): studies on its metabolism and toxicological detection in rat urine using gas chromatographic\/mass spectrometric techniques","volume":"44","author":"Sauer","year":"2009","journal-title":"J. Mass Spectrom."},{"key":"10.1016\/bs.acc.2020.10.001_bb0425","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jchromb.2005.07.003","article-title":"Studies on the metabolism and toxicological detection of the new designer drug 4\u2032-methyl-alpha-pyrrolidinobutyrophenone (MPBP) in rat urine using gas chromatography-mass spectrometry","volume":"824","author":"Peters","year":"2005","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"key":"10.1016\/bs.acc.2020.10.001_bb0430","series-title":"Schedules of Controlled Substances: Placement of Methylone Into Schedule I","first-page":"21818","volume":"vol. 78","author":"Drug Enforcement Administration","year":"2013"},{"key":"10.1016\/bs.acc.2020.10.001_bb0435","series-title":"Schedules of Controlled Substances: Placement of 10 Synthetic Cathinones Into Schedule I","first-page":"12171","volume":"vol. 82","author":"Drug Enforcement Administration","year":"2017"},{"key":"10.1016\/bs.acc.2020.10.001_bb0440","series-title":"Schedules of Controlled Substances: Temporary Placement of N-Ethylpentylone in Schedule I","first-page":"27520","volume":"vol. 83","author":"Drug Enforcement Administration","year":"2018"},{"key":"10.1016\/bs.acc.2020.10.001_bb0445","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/ajcp\/aqx138","article-title":"Newly emerging drugs of abuse and their detection methods: an ACLPS critical review","volume":"149","author":"Liu","year":"2018","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/bs.acc.2020.10.001_bb0450","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3810\/pgm.2009.07.2035","article-title":"Urine toxicology testing in chronic pain management","volume":"121","author":"Cone","year":"2009","journal-title":"Postgrad. Med."},{"key":"10.1016\/bs.acc.2020.10.001_bb0455","first-page":"22","article-title":"Using cheminformatics to predict cross reactivity of \"designer drugs\" to their currently available immunoassays","volume":"6","author":"Krasowski","year":"2014","journal-title":"J. Chem."},{"key":"10.1016\/bs.acc.2020.10.001_bb0460","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1471-227X-9-5","article-title":"Using molecular similarity to highlight the challenges of routine immunoassay-based drug of abuse\/toxicology screening in emergency medicine","volume":"9","author":"Krasowski","year":"2009","journal-title":"BMC Emerg. Med."},{"key":"10.1016\/bs.acc.2020.10.001_bb0465","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1373\/clinchem.2008.118638","article-title":"Chemoinformatic methods for predicting interference in drug of abuse\/toxicology immunoassays","volume":"55","author":"Krasowski","year":"2009","journal-title":"Clin. Chem."},{"key":"10.1016\/bs.acc.2020.10.001_bb0470","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.forsciint.2014.04.020","article-title":"Evaluation of a homogenous enzyme immunoassay for the detection of synthetic cannabinoids in urine","volume":"241","author":"Barnes","year":"2014","journal-title":"Forensic Sci. Int."},{"key":"10.1016\/bs.acc.2020.10.001_bb0475","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3109\/15563650.2013.768344","article-title":"Cross-reactivity studies and predictive modeling of \"Bath Salts\" and other amphetamine-type stimulants with amphetamine screening immunoassays","volume":"51","author":"Petrie","year":"2013","journal-title":"Clin. Toxicol. (Phila.)"},{"key":"10.1016\/bs.acc.2020.10.001_bb0480","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1093\/jat\/bku133","article-title":"Determination of designer drug cross-reactivity on five commercial immunoassay screening kits","volume":"39","author":"Regester","year":"2015","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/bs.acc.2020.10.001_bb0485","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0378-4347(92)80526-V","article-title":"Systematic toxicological analysis of drugs and their metabolites by gas chromatography-mass spectrometry","volume":"580","author":"Maurer","year":"1992","journal-title":"J. Chromatogr."},{"key":"10.1016\/bs.acc.2020.10.001_bb0490","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/mas.1280100104","article-title":"Mass spectrometry with ion sources operating at atmospheric pressure","volume":"10","author":"Bruins","year":"1991","journal-title":"Mass Spectrom. Rev."},{"key":"10.1016\/bs.acc.2020.10.001_bb0495","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1515\/CCLM.2004.250","article-title":"Position of chromatographic techniques in screening for detection of drugs or poisons in clinical and forensic toxicology and\/or doping control","volume":"42","author":"Maurer","year":"2004","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/bs.acc.2020.10.001_bb0500","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.cll.2016.07.001","article-title":"Liquid chromatography-tandem mass spectrometry: an emerging technology in the toxicology laboratory","volume":"36","author":"Zhang","year":"2016","journal-title":"Clin. Lab. Med."},{"key":"10.1016\/bs.acc.2020.10.001_bb0505","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1002\/rcm.2996","article-title":"MSE with mass defect filtering for in vitro and in vivo metabolite identification","volume":"21","author":"Bateman","year":"2007","journal-title":"Rapid Commun. Mass Spectrom."},{"key":"10.1016\/bs.acc.2020.10.001_bb0510","doi-asserted-by":"crossref","DOI":"10.1074\/mcp.O111.016717","article-title":"Targeted data extraction of the MS\/MS spectra generated by data-independent acquisition: a new concept for consistent and accurate proteome analysis","volume":"11","author":"Gillet","year":"2012","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/bs.acc.2020.10.001_bb0515","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1373\/clinchem.2014.222976","article-title":"Liquid chromatography high-resolution TOF analysis: investigation of MSE for broad-spectrum drug screening","volume":"60","author":"Chindarkar","year":"2014","journal-title":"Clin. Chem."},{"key":"10.1016\/bs.acc.2020.10.001_bb0520","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1373\/clinchem.2018.300756","article-title":"Optimization and comparison of information-dependent acquisition (IDA) to sequential window acquisition of all theoretical fragment ion spectra (SWATH) for high-resolution mass spectrometry in clinical toxicology","volume":"65","author":"Whitman","year":"2019","journal-title":"Clin. Chem."},{"key":"10.1016\/bs.acc.2020.10.001_bb0525","doi-asserted-by":"crossref","first-page":"733","DOI":"10.3109\/15563650.2012.713108","article-title":"Role of liquid chromatography-high-resolution mass spectrometry (LC-HR\/MS) in clinical toxicology","volume":"50","author":"Wu","year":"2012","journal-title":"Clin. Toxicol. (Phila.)"},{"key":"10.1016\/bs.acc.2020.10.001_bb0530","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.aca.2016.04.046","article-title":"Review: LC coupled to low- and high-resolution mass spectrometry for new psychoactive substance screening in biological matrices\u2014where do we stand today?","volume":"927","author":"Meyer","year":"2016","journal-title":"Anal. Chim. Acta"},{"key":"10.1016\/bs.acc.2020.10.001_bb0535","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s00216-014-8262-1","article-title":"Applying 'Sequential Windowed Acquisition of All Theoretical Fragment Ion Mass Spectra' (SWATH) for systematic toxicological analysis with liquid chromatography-high-resolution tandem mass spectrometry","volume":"407","author":"Arnhard","year":"2015","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/bs.acc.2020.10.001_bb0540","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1093\/jat\/bkt071","article-title":"Drug screening in medical examiner casework by high-resolution mass spectrometry (UPLC-MSE-TOF)","volume":"37","author":"Rosano","year":"2013","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/bs.acc.2020.10.001_bb0545","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s11419-015-0270-0","article-title":"Comprehensive review of the detection methods for synthetic cannabinoids and cathinones","volume":"33","author":"Namera","year":"2015","journal-title":"Forensic Toxicol."},{"key":"10.1016\/bs.acc.2020.10.001_bb0550","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1111\/1556-4029.12260","article-title":"Deaths involving methylenedioxypyrovalerone (MDPV) in Upper East Tennessee","volume":"58","author":"Wright","year":"2013","journal-title":"J. Forensic Sci."},{"key":"10.1016\/bs.acc.2020.10.001_bb0555","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1056\/NEJMcpc1304051","article-title":"Case records of the Massachusetts General Hospital. Case 40\u20132013. A 36-year-old man with agitation and paranoia","volume":"369","author":"Benzer","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.acc.2020.10.001_bb0560","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1586\/erv.11.145","article-title":"Current challenges for the creation of effective vaccines against drugs of abuse","volume":"10","author":"Moreno","year":"2011","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/bs.acc.2020.10.001_bb0565","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1007\/s00213-020-05558-0","article-title":"Active vaccination reduces reinforcing effects of MDPV in male Sprague-Dawley rats trained to self-administer cocaine","volume":"237","author":"McClenahan","year":"2020","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/bs.acc.2020.10.001_bb0570","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.vaccine.2019.10.008","article-title":"Design, synthesis and biological evaluation of a bi-specific vaccine against alpha-pyrrolidinovalerophenone (alpha-PVP) and 3,4-methylenedioxypyrovalerone (MDPV) in rats","volume":"38","author":"McClenahan","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/bs.acc.2020.10.001_bb0575","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neuropharm.2016.12.005","article-title":"Active vaccination attenuates the psychostimulant effects of alpha-PVP and MDPV in rats","volume":"116","author":"Nguyen","year":"2017","journal-title":"Neuropharmacology"}],"container-title":["Advances in Clinical Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S006524232030127X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S006524232030127X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T19:39:40Z","timestamp":1758742780000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S006524232030127X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"ISBN":["9780128246160"],"references-count":114,"URL":"https:\/\/doi.org\/10.1016\/bs.acc.2020.10.001","relation":{},"ISSN":["0065-2423"],"issn-type":[{"value":"0065-2423","type":"print"}],"subject":[],"published":{"date-parts":[[2021]]}}}